Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Anti-Aging
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Response rates high with imiquimod for multiple basal cell
Washington D.C. -- Imiquimod 5 percent cream produces histologic response rates in excess of 70 percent in the treatment of multiple superficial basal cell carcinomas, according to study data presented at the 62nd annual meeting of the American Academy of Dermatology.
Related Videos
Related Content
